NSEGeneral Updates2d ago · 23 Sept 2026, 06:20 pm

General Updates

Emcure Pharmaceuticals Limited · EMCURE

✦ AI SummaryMgmt Change

Emcure Pharmaceuticals Limited has informed the Exchange about change in composition of the Board of the Company, following the 45th Annual General Meeting (AGM) held on September 21, 2026. The AGM approved the retirement of Mr. Berjis Desai, re-appointment of Dr. Mukund Gurjar and Mr. Satish Mehta, and appointment of Mr. Raghu Kumar as Independent Director.

Analysis Scores

Earnings Impact2/10
Growth Catalyst3/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

EMCURE: Emcure Pharmaceuticals Limited has informed the Exchange about change in composition of the Board of the Company.

Attachments (1)

📄

EMCURE_23092026182025_EPLUpdateonAGMresolutions.pdf

pdf

Download →
View document text
Emcure Ref: EPL/CS/SE/0084/2026 Date: September 23, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, P J Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400 051 Mumbai- 400 001 Script Symbol: EMCURE Scrip Code/Symbol: 544210/ EMCURE Dear Sir/Madam, Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Change in composition of the Board of the Company We refer to our disclosure dated May 05, 2026 and August 06, 2026 and pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), this is to inform you that the Members of the Company, at the 45th Annual General Meeting (“AGM”) of the Company held on Monday, September 21, 2026 at 11.00 a.m. (IST) have, inter-alia, approved:  Retirement of Mr. Berjis Desai (DIN: 00153675), Chairman and Non-Executive Non-Independent Director upon the conclusion of this AGM, i.e., September 21, 2026.  Re-appointment of Dr. Mukund Gurjar (DIN: 00026843) as a Whole-time Director of the Company for a further period of one (1) year commencing from August 28, 2026.  Re-appointment of Mr. Satish Mehta (DIN: 00118691) as a Managing Director & Chief Executive Officer of the Company a further period of 5 (five) years commencing from April 01, 2027.  Appointment of Mr. Raghu Kumar (DIN: 01983106) as an Independent Director of the Company for first term of three (3) consecutive years, with effect from August 06, 2026. The voting results of 45th AGM of the Members of the Company have been submitted with both the Stock Exchanges on September 23, 2026. You are requested to take the above information on your records. Thanking you, For Emcure Pharmaceuticals Limited Amruta Yangalwar Company Secretary & Compliance Officer ICSI Membership Number: A25687 Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251